ArticleTherapeutics and clinical risk management2017

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice.

Kathleen A Fairman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.